Skip to content

The Effect of Two Dietary Interventions on the Symptomatic Control of People Living With Anxiety Disorders.

The Effect of Two Dietary Interventions on the Symptomatic Control of People Living With Anxiety Disorders.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04586829
Enrollment
35
Registered
2020-10-14
Start date
2020-10-15
Completion date
2024-12-01
Last updated
2022-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders

Brief summary

This randomised controlled trial will evaluate the effect of a ketogenic diet vs a conventional diet on the symptoms of patients living with anxiety disorders using a validate self-reported inventory.

Detailed description

It has been theorized that ketogenic diet could improve symptom control in patients living with anxiety disorders. Animal models support this hypothesis but to this date, studies in humans are lacking. The investigators will randomise patients with a confirmed diagnosis of anxiety disorders to follow a ketogenic diet (\<50 grs of carbohydrate per day) or a conventional diet (50% carbohydrate, 30% lipids, 20% protein) for one month. Symptom control will be assessed weekly using Beck's inventory for Anxiety. Diet adherence will be measured using standardised food frequency logs and acetoacetate urine strips.

Interventions

OTHERDiet

\<50 grams of total carbohydrates per day. Monosaturated fats consumption will be encouraged over saturated fats.

Sponsors

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Randomised controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with a confirmed diagnosis of Anxiety Disorder by Psychiatrist.

Exclusion criteria

* Patients with the diagnosis of drug abuse, cognitive impairment or dementia, porphyria, carnitine translocase deficiency and carnitine palmitoyl transferase deficiency.

Design outcomes

Primary

MeasureTime frameDescription
Symptom controlOne monthTotal points in Beck's Inventory for Anxiety. Scores range between 0 to 63 and higher numbers mean a worse outcome.

Secondary

MeasureTime frameDescription
Subjective self perceived controlOne monthSelf-assessed and reported symptom ranging between 0 - 100. Higher numbers mean a better outcome.

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026